[
  {
    "id": 71,
    "question": "30 y.o male found unconscious at street. What you expect as the mechanism of injury for attached CT",
    "option_a": "(Aneurysmal) is incorrect because aneurysmal ruptures typically produce subarachnoid hemorrhage in a non",
    "option_b": "(Trauma) is correct as the patient\u2019s history and clinical situation strongly indicate a traumatic injury. Option C (Hypertension) is incorrect because hypertensive hemorrhages generally occur in older individuals with a history of poorly controlled blood pressure and typically involve deep brain regions.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis case involves a young male found unconscious outdoors, which strongly suggests a traumatic mechanism. In trauma cases, the evaluation focuses on identifying intracranial injuries such as hematomas, contusions, or diffuse axonal injury.\n\n**Pathophysiology**\n\nTraumatic brain injuries (TBIs) result from external mechanical forces that disrupt normal cerebral function. Vessel rupture due to blunt force trauma can lead to various hemorrhages (e.g., epidural, subdural) and parenchymal contusions.\n\n**Clinical Correlation**\n\nA 30-year-old male found unconscious is more likely to have suffered head trauma rather than a spontaneous hemorrhage from hypertension or an aneurysmal rupture. The CT appearance in traumatic injury typically includes localized hemorrhages or contusions, often with a pattern distinct from spontaneous bleeds seen in hypertensive or aneurysmal events.\n\n**Diagnostic Approach**\n\nImmediate non-contrast CT imaging is used to identify intracranial hemorrhages and traumatic injuries. Differential diagnoses include aneurysmal subarachnoid hemorrhage (which usually presents with a severe headache and a different bleeding pattern on CT) and hypertensive hemorrhage (characteristically seen in older patients with chronic hypertension involving deep brain structures).\n\n**Management Principles**\n\nManagement of TBI includes rapid neurosurgical evaluation, maintenance of airway, breathing, and circulation, and intracranial pressure monitoring when indicated. Surgical intervention may be necessary if there is significant hematoma with mass effect. In pregnant patients, imaging protocols are adjusted to minimize fetal exposure while ensuring maternal safety, and similar principles apply for lactating patients with careful counseling regarding radiation exposure.\n\n**Option Analysis**\n\nOption A (Aneurysmal) is incorrect because aneurysmal ruptures typically produce subarachnoid hemorrhage in a non-traumatic context with a characteristic severe headache. Option B (Trauma) is correct as the patient\u2019s history and clinical situation strongly indicate a traumatic injury. Option C (Hypertension) is incorrect because hypertensive hemorrhages generally occur in older individuals with a history of poorly controlled blood pressure and typically involve deep brain regions.\n\n**Clinical Pearls**\n\n1. In young patients found unconscious, always consider trauma as the primary cause of intracranial injury. 2. CT imaging is crucial to distinguishing between traumatic and spontaneous intracranial hemorrhages. 3. Traumatic hemorrhages have characteristic CT patterns that differ from hypertensive or aneurysmal bleeds.\n\n**Current Evidence**\n\nRecent trauma guidelines stress the importance of rapid CT imaging for TBI evaluation and emphasize early neurosurgical consultation. Ongoing research is focused on minimizing radiation exposure in vulnerable populations, such as pregnant women, while ensuring accurate diagnosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 72,
    "question": "Global aphasia after one month (? asking about prognosis)",
    "option_a": "(Broca\u2019s aphasia) is incorrect because it represents a less severe, non",
    "option_b": "(Global aphasia) is correct, reflecting the patient\u2019s persistent and extensive language deficits. Option C (Anomia) is incorrect as it refers only to word",
    "option_c": "",
    "option_d": "(Wernicke\u2019s aphasia) is incorrect because it does not match the global nature of the deficits observed.",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAphasia is a language disorder caused by damage to specific regions of the brain. Global aphasia involves severe impairment in both expressive and receptive language functions. Persistence of global aphasia after one month indicates extensive cortical damage, generally implying a poorer prognosis.\n\n**Pathophysiology**\n\nGlobal aphasia results from large lesions that affect essential language centers, typically involving both Broca\u2019s (expressive) and Wernicke\u2019s (receptive) areas, often due to a large middle cerebral artery (MCA) infarct. The extensive damage disrupts communication networks in the brain, leading to profound language deficits.\n\n**Clinical Correlation**\n\nA patient with persistent global aphasia at one month post-stroke is unlikely to have transitioned to a less severe form such as Broca\u2019s or Wernicke\u2019s aphasia. This sustained deficit reflects a large area of infarction with limited potential for rapid recovery.\n\n**Diagnostic Approach**\n\nEvaluation includes detailed language assessments performed by a speech-language pathologist and correlating neuroimaging studies (CT/MRI) to determine the extent of cortical damage. Differential diagnoses in aphasia include Broca\u2019s aphasia (non-fluent, relatively preserved comprehension), Wernicke\u2019s aphasia (fluent but with impaired comprehension), and anomic aphasia (word-finding difficulties with milder deficits).\n\n**Management Principles**\n\nThe mainstay of management for aphasia is intensive, early speech and language therapy. While prognosis in global aphasia is guarded, early rehabilitation, multidisciplinary care, and patient-specific interventions can optimize functional recovery. For pregnant and lactating patients, non-invasive treatments such as speech therapy are safe and remain the standard of care.\n\n**Option Analysis**\n\nOption A (Broca\u2019s aphasia) is incorrect because it represents a less severe, non-fluent aphasia with relatively preserved comprehension. Option B (Global aphasia) is correct, reflecting the patient\u2019s persistent and extensive language deficits. Option C (Anomia) is incorrect as it refers only to word-finding difficulties, and Option D (Wernicke\u2019s aphasia) is incorrect because it does not match the global nature of the deficits observed.\n\n**Clinical Pearls**\n\n1. Persistent global aphasia after one month typically indicates a large infarct with a poorer prognosis. 2. Early, aggressive speech and language therapy is crucial, though recovery may be limited. 3. Detailed language assessments help to monitor recovery and tailor rehabilitative efforts.\n\n**Current Evidence**\n\nRecent research emphasizes the role of neuroplasticity and early intervention in post-stroke aphasia. Although recovery in global aphasia remains challenging, emerging therapies and advanced neurorehabilitation techniques continue to evolve, with ongoing studies investigating adjuvant therapies to improve outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 73,
    "question": "Small PFO & AF in young female who developed stroke, ttt",
    "option_a": "(Closure): Incorrect because closing a small PFO does not address the embolic risk from AF. Option b (Warfarin): While anticoagulation is indicated in many AF cases, warfarin is not preferred given the availability of DOACs and may be overtreatment in a low AF burden scenario. Option c (ASA): Correct in this context where the clinical scenario implies low AF burden or diagnostic uncertainty, making antiplatelet therapy a conservative and appropriate choice.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question concerns the management of stroke in a young female with a small patent foramen ovale (PFO) and atrial fibrillation (AF). The key concept is discerning the stroke source. In patients with cryptogenic stroke and a small PFO, closure is typically reserved when no other embolic source exists. However, when AF is present\u2014even if paroxysmal or of low burden\u2014it can be considered a source of cardioembolism. In selected cases, especially when the AF burden isn\u2019t definitively high or when its role is ambiguous, a conservative approach with antiplatelet therapy may be chosen.\n\n**Pathophysiology**\n\nA small PFO permits the possibility of paradoxical embolism, but its risk is generally lower compared to a significant shunt. In atrial fibrillation, stasis in the left atrium promotes thrombus formation that may embolize to the brain. When both conditions coexist, the underlying pathophysiological concern is determining which source is dominant. Current evidence suggests that in patients with low-risk AF or uncertainty about stroke mechanism, aggressive anticoagulation may not provide additional benefit compared to antiplatelet therapy, particularly if the PFO is small.\n\n**Clinical Correlation**\n\nClinically, a young stroke patient might present with focal neurologic deficits and workup may reveal a small PFO on echocardiography and episodes of paroxysmal AF on prolonged monitoring. The decision for treatment is influenced by the frequency and burden of AF as well as the anatomical significance of the PFO. The clinical challenge lies in attributing the stroke to either a paradoxical embolism via PFO or an embolism from AF.\n\n**Diagnostic Approach**\n\nEvaluation includes brain imaging (MRI/CT) to confirm infarction, transthoracic or transesophageal echocardiography to assess for PFO, and cardiac monitoring (e.g., Holter) for detecting paroxysmal AF. Differential diagnoses include other causes of cryptogenic stroke such as hypercoagulable states, arterial dissection, and vasculitis. Differentiation relies on combining imaging studies with clinical risk factor assessments.\n\n**Management Principles**\n\nLatest guidelines recommend antiplatelet therapy (aspirin) for secondary prevention in patients with low-risk or uncertain sources where the burden of AF is minimal. First-line treatment is usually aspirin, particularly in younger patients or those in whom the risk\u2013benefit profile for full anticoagulation is unclear. In contrast, patients with definite, sustained AF typically require anticoagulation with direct oral anticoagulants (DOACs), which are preferred over warfarin for their predictable effect and safety profile. In pregnancy and lactation, low-dose aspirin is generally considered safe, although the decision must account for individual patient risk factors and breastfeeding status.\n\n**Option Analysis**\n\nOption a (Closure): Incorrect because closing a small PFO does not address the embolic risk from AF. Option b (Warfarin): While anticoagulation is indicated in many AF cases, warfarin is not preferred given the availability of DOACs and may be overtreatment in a low AF burden scenario. Option c (ASA): Correct in this context where the clinical scenario implies low AF burden or diagnostic uncertainty, making antiplatelet therapy a conservative and appropriate choice.\n\n**Clinical Pearls**\n\n1. In patients with cryptogenic stroke, discerning the stroke source (PFO vs. AF) is essential to guide management. 2. PFO closure is generally reserved for patients without another clear embolic source. 3. Low-dose aspirin is relatively safe in young patients and during pregnancy/lactation when full anticoagulation is not clearly indicated.\n\n**Current Evidence**\n\nRecent studies and guidelines continue to stress the need for individualized therapy in stroke management. The data support the use of DOACs in definitive AF cases, whereas in cryptogenic stroke with a small PFO and minimal AF burden, aspirin remains a viable first-line option. Ongoing research is further refining criteria to differentiate stroke sources.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 74,
    "question": "Lobar hemorrhage with high INR, ttt:",
    "option_a": "(PCC): Correct",
    "option_b": "(FFP): Incorrect",
    "option_c": "(Vitamin K alone): Incorrect",
    "option_d": "(Protamine): Incorrect",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question deals with the acute management of warfarin-associated intracerebral hemorrhage (ICH) in a patient with a lobar hemorrhage and an elevated International Normalized Ratio (INR). The primary goal is rapid reversal of the coagulopathy to prevent hematoma expansion and further neurological injury.\n\n**Pathophysiology**\n\nWarfarin interferes with the synthesis of vitamin K\u2013dependent clotting factors (II, VII, IX, and X). In the setting of an intracranial hemorrhage, the lack of these factors prolongs bleeding. Prothrombin complex concentrates (PCC) provide concentrated clotting factors, rapidly normalizing the INR and thereby limiting further bleeding.\n\n**Clinical Correlation**\n\nPatients on warfarin presenting with lobar hemorrhage require urgent correction of their coagulopathy. A high INR correlates with an increased risk of bleeding expansion. Timely reversal can mitigate hematoma growth and improve clinical outcomes.\n\n**Diagnostic Approach**\n\nInitial workup includes a non-contrast head CT confirming hemorrhage, laboratory testing to determine INR and coagulation status, and a careful review of the medication history. Differential diagnoses include hemorrhagic transformation of an ischemic stroke and other coagulopathies.\n\n**Management Principles**\n\nCurrent guidelines recommend using PCC as first-line therapy because of its rapid action in reversing warfarin-induced coagulopathy. Vitamin K should be administered concurrently to achieve sustained reversal, although its onset is delayed (6\u201324 hours). Fresh frozen plasma (FFP) is a secondary option if PCC is unavailable due to its slower action and larger volume requirements. Protamine sulfate is reserved for the reversal of heparin and has no effect on warfarin reversal. In pregnancy and lactation, rapid reversal remains critical; PCC along with vitamin K is used despite warfarin\u2019s contraindication in pregnancy, as the acute situation mandates reversal of coagulopathy.\n\n**Option Analysis**\n\nOption a (PCC): Correct \u2013 Provides rapid reversal of warfarin\u2019s effects by delivering clotting factors. Option b (FFP): Incorrect \u2013 Although it provides clotting factors, its slower action and higher volume load make it less desirable in an acute setting. Option c (Vitamin K alone): Incorrect \u2013 While necessary for sustained reversal, its delayed onset precludes its use as the sole agent in acute hemorrhage management. Option d (Protamine): Incorrect \u2013 Protamine reverses heparin, not warfarin.\n\n**Clinical Pearls**\n\n1. PCC is the fastest means to reverse warfarin-induced coagulopathy in acute ICH. 2. Always use vitamin K alongside PCC for prolonged reversal. 3. Distinguish between warfarin reversal agents and those used for heparin.\n\n**Current Evidence**\n\nRecent guidelines from the American Heart Association emphasize that PCC is preferred over FFP for reversing warfarin-associated ICH due to its rapid efficacy and lower complication profile. Studies have reinforced its use in improving clinical outcomes by rapidly restoring coagulation.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 75,
    "question": "Severe MCA stenosis in elderly with stroke, ttt",
    "option_a": "(ASA): Correct",
    "option_b": "(Angio & stenting): Incorrect",
    "option_c": "(ASA & Warfarin): Incorrect",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question focuses on the management of severe middle cerebral artery (MCA) stenosis in an elderly patient with stroke. The central principle is that medical management, primarily with antiplatelet therapy, is the mainstay of treatment for intracranial atherosclerotic disease.\n\n**Pathophysiology**\n\nSevere MCA stenosis is usually the result of atherosclerotic plaque buildup, which may lead to turbulent flow and a propensity for thrombosis. This mechanism increases the risk of ischemic stroke by limiting cerebral perfusion and facilitating embolism from unstable plaques.\n\n**Clinical Correlation**\n\nPatients typically present with symptoms of ischemic stroke such as hemiparesis, aphasia, or sensory deficits. Imaging (CT/MRI angiography) identifies the degree of stenosis. Recognizing the underlying pathology directs the treatment toward limiting further ischemic events while managing vascular risk factors.\n\n**Diagnostic Approach**\n\nThe diagnostic workup involves brain imaging to document the stroke and vascular studies (MRA, CTA, or catheter angiography) to assess the severity of intracranial stenosis. Differential diagnoses include embolic stroke from cardiac sources and small vessel lacunar infarcts. Risk factor evaluation (hypertension, diabetes, hyperlipidemia) is essential.\n\n**Management Principles**\n\nFirst-line management is aggressive medical therapy, which includes antiplatelet agents (aspirin as the cornerstone), risk factor modification (blood pressure, lipid control), and lifestyle changes. Second-line therapies (such as angioplasty and stenting) are generally reserved for patients who fail optimal medical therapy and are approached with caution due to periprocedural risks. In pregnancy and lactation, aspirin (in low-dose form) is typically considered safe for stroke prevention, whereas invasive procedures are usually deferred unless absolutely necessary.\n\n**Option Analysis**\n\nOption a (ASA): Correct \u2013 Aspirin is the recommended first-line antiplatelet therapy supported by evidence from trials like SAMMPRIS and WASID. Option b (Angio & stenting): Incorrect \u2013 Invasive procedures carry a high risk and are not first-line due to increased periprocedural complications. Option c (ASA & Warfarin): Incorrect \u2013 Combining anticoagulation with antiplatelet therapy has not been shown to be superior to antiplatelet monotherapy and increases the risk of hemorrhage.\n\n**Clinical Pearls**\n\n1. Aspirin remains the cornerstone in the management of intracranial atherosclerotic disease. 2. Invasive procedures should be reserved for refractory cases, given the high associated risks. 3. Optimal management includes aggressive control of vascular risk factors.\n\n**Current Evidence**\n\nRecent clinical trials such as SAMMPRIS and WASID reinforce that aggressive medical management, particularly with antiplatelet therapy, is superior to invasive interventions in patients with severe MCA stenosis. Current guidelines continue to endorse aspirin as the primary antiplatelet agent in this setting.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 76,
    "question": "Maxillary, nasal lesion with proptosis, causes of CVT:",
    "option_a": "(Direct invasion): Correct",
    "option_b": "(Veins): Incorrect",
    "option_c": "",
    "option_d": "oes not explain the mechanism. Option c (LN [Lymph nodes]): Incorrect",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThis question examines the mechanism by which maxillary or nasal lesions that produce proptosis can lead to cerebral venous thrombosis (CVT). The central concept is the potential for direct extension of infection or malignancy from adjacent extracranial structures to intracranial venous sinuses.\n\n**Pathophysiology**\n\nMaxillary or nasal lesions, particularly those with an invasive component, may extend directly into the cerebral venous system. The valveless venous networks interconnect the extracranial and intracranial compartments, allowing pathogens or tumor cells to directly invade the dural sinuses, causing endothelial injury and subsequent thrombosis.\n\n**Clinical Correlation**\n\nPatients with such lesions typically present with signs of orbital involvement like proptosis, headache, and sometimes visual disturbances. CVT may present with additional symptoms including seizures and altered mental status. Recognizing direct invasive spread is crucial for early diagnosis and management.\n\n**Diagnostic Approach**\n\nDiagnostic imaging plays a vital role. Magnetic resonance venography (MRV) or CT venography (CTV) can delineate the presence of thrombosis. Differentiation from other causes of proptosis (e.g., orbital cellulitis, cavernous sinus thrombosis from other etiologies) is achieved by correlating clinical history with imaging findings.\n\n**Management Principles**\n\nThe primary treatment is anticoagulation to prevent thrombus propagation, even in the context of hemorrhagic transformation, along with addressing the underlying lesion (via antibiotics, surgery, or oncological management). In the setting of pregnancy and lactation, low molecular weight heparin is commonly used for CVT due to its safety profile compared to unfractionated heparin or warfarin.\n\n**Option Analysis**\n\nOption a (Direct invasion): Correct \u2013 It accurately describes the mechanism by which a maxillary, nasal lesion with proptosis causes CVT via anatomical venous connections. Option b (Veins): Incorrect \u2013 Too vague; while veins are the site of thrombosis, this option does not explain the mechanism. Option c (LN [Lymph nodes]): Incorrect \u2013 Lymphatic structures do not directly communicate with the intracranial venous system and are not involved in the pathogenesis of CVT in this scenario.\n\n**Clinical Pearls**\n\n1. Direct extension of infection or malignancy through valveless venous channels is a well-known cause of CVT. 2. Proptosis in the setting of nasal or maxillary lesions should prompt evaluation for intracranial complications. 3. Early imaging with MRV or CTV is critical in making the diagnosis.\n\n**Current Evidence**\n\nRecent clinical literature emphasizes the importance of recognizing the anatomical pathways for infection spread in the head and neck region. Updated guidelines support early anticoagulation and management of the primary lesion to improve outcomes in CVT.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 77,
    "question": "The management of a patient who developed angioedema after starting tPA:",
    "option_a": "Reassurance",
    "option_b": "intubate",
    "option_c": "anti-histamine & steroids",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAngioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise.\n\n**Pathophysiology**\n\ntPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management.\n\n**Clinical Correlation**\n\nPatients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use.\n\n**Diagnostic Approach**\n\nThis diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical.\n\n**Management Principles**\n\nThe first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management.\n\n**Option Analysis**\n\nOption A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided.\n\n**Clinical Pearls**\n\n\u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication.\n\n**Current Evidence**\n\nRecent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 78,
    "question": "83-Year-old man, presented with 3 hr Hx of stroke, CT brain done What to do next \u0646\u0633\u064a\u062a \u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u062d\u0627\u0644\u0629",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAngioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise.\n\n**Pathophysiology**\n\ntPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management.\n\n**Clinical Correlation**\n\nPatients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use.\n\n**Diagnostic Approach**\n\nThis diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical.\n\n**Management Principles**\n\nThe first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management.\n\n**Option Analysis**\n\nOption A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided.\n\n**Clinical Pearls**\n\n\u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication.\n\n**Current Evidence**\n\nRecent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 79,
    "question": "Tongue deviation to the Lt",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAngioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise.\n\n**Pathophysiology**\n\ntPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management.\n\n**Clinical Correlation**\n\nPatients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use.\n\n**Diagnostic Approach**\n\nThis diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical.\n\n**Management Principles**\n\nThe first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management.\n\n**Option Analysis**\n\nOption A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided.\n\n**Clinical Pearls**\n\n\u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication.\n\n**Current Evidence**\n\nRecent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "id": 80,
    "question": "Case of chronic fluctuating paraparesis\nimage attached",
    "option_a": "(Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first",
    "option_b": "",
    "option_c": "(anti",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAngioedema is a localized, self\u2010limited edema of the deep dermis and subcutaneous tissues. When it occurs in the context of tPA administration (often in patients with underlying ACE\u2010inhibitor use), it is thought to be secondary to an abnormal release of vasoactive mediators. The clinical scenario requires rapid recognition because swelling of the tongue, lips, or oropharynx can progress to airway compromise.\n\n**Pathophysiology**\n\ntPA not only lyses fibrin clots but also activates plasmin which can trigger the release of bradykinin. Increased bradykinin levels lead to vasodilation and increased vascular permeability. Although the process is bradykinin\u2010mediated (instead of the classic histaminergic allergic reaction), many of the treatments overlap. In some cases, the reaction may be severe enough to require aggressive airway management.\n\n**Clinical Correlation**\n\nPatients receiving tPA for ischemic stroke may develop angioedema within the infusion period. Clinically, swelling typically involves the tongue, lips, and sometimes the floor of the mouth. Although it may start as a localized process, rapid progression can lead to difficulty breathing and potential airway loss, especially in patients with predisposing factors such as concurrent ACE inhibitor use.\n\n**Diagnostic Approach**\n\nThis diagnosis is based on clinical observation. The differential includes allergic reaction/anaphylaxis from other agents, or soft tissue infections. In the setting of recent tPA administration and a typical distribution (orolingual), tPA-induced angioedema is the most likely diagnosis. Monitoring for airway patency and assessing progression is critical.\n\n**Management Principles**\n\nThe first step in management is to immediately stop the tPA infusion. In mild cases where airway compromise is not imminent, treatment with anti-histamines (H1 blockers) and corticosteroids is recommended to reduce inflammation. Epinephrine may be considered if there are signs of a more typical anaphylactic reaction. However, if there is any concern for airway compromise, securing the airway (with intubation) is imperative. In pregnant or lactating patients, these medications are used with caution but are acceptable when maternal airway protection is needed. Consultation with anesthesia and otolaryngology may be warranted for airway management.\n\n**Option Analysis**\n\nOption A (Reassurance) is insufficient as the risk of airway compromise requires active intervention. Option B (Intubate) is reserved for cases with significant airway compromise and is not the first-line approach in the absence of severe symptoms. Option C (anti-histamine & steroids) is the appropriate first-line management for mild to moderate angioedema post-tPA, making it the correct answer. Option D is not provided.\n\n**Clinical Pearls**\n\n\u2022 tPA-induced angioedema is most commonly seen in patients on ACE inhibitors. \u2022 Always monitor for airway compromise and be ready to secure the airway. \u2022 Early cessation of tPA infusion is critical in the management of this complication.\n\n**Current Evidence**\n\nRecent studies and guidelines emphasize that while the angioedema associated with tPA is bradykinin-mediated, initial management with anti-histamines and steroids remains standard practice, along with vigilant airway monitoring. There is emerging interest in specific bradykinin inhibitors (like icatibant), but these are not yet standard.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_18.png"
  }
]